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The isolated carboxy-terminal domain of human
mitochondrial leucyl-tRNA synthetase rescues the
pathological phenotype of mitochondrial tRNA
mutations in human cells
Elena Perli1,2, Carla Giordano1, Annalinda Pisano1,3, Arianna Montanari1,2,4, Antonio F Campese5,
Aurelio Reyes6, Daniele Ghezzi7, Alessia Nasca7, Helen A Tuppen8, Maurizia Orlandi1,5,
Patrizio Di Micco9, Elena Poser9, Robert W Taylor8, Gianni Colotti10, Silvia Francisci2,4, Veronica Morea10,
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Abstract
Mitochondrial (mt) diseases are multisystem disorders due to
mutations in nuclear or mtDNA genes. Among the latter, more
than 50% are located in transfer RNA (tRNA) genes and are
responsible for a wide range of syndromes, for which no effective
treatment is available at present. We show that three human mt
aminoacyl-tRNA syntethases, namely leucyl-, valyl-, and isoleucyl-
tRNA synthetase are able to improve both viability and
bioenergetic proficiency of human transmitochondrial cybrid cells
carrying pathogenic mutations in the mt-tRNAIle gene. Impor-
tantly, we further demonstrate that the carboxy-terminal domain
of human mt leucyl-tRNA synthetase is both necessary and suffi-
cient to improve the pathologic phenotype associated either with
these mild mutations or with the severe m.3243A>G mutation in
the mt-tRNALeu(UUR) gene. Furthermore, we provide evidence that
this small, non-catalytic domain is able to directly and specifically
interact in vitro with human mt-tRNALeu(UUR) with high affinity
and stability and, with lower affinity, with mt-tRNAIle. Taken
together, our results sustain the hypothesis that the carboxy-
terminal domain of human mt leucyl-tRNA synthetase can be used
to correct mt dysfunctions caused by mt-tRNA mutations.
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Introduction
Mitochondrial (mt) diseases are multisystem disorders due to mutations
in nuclear or mtDNA genes. Among the latter mutations, more than
50% are located in transfer RNA (tRNA) genes (MITOMAP: A Human
Mitochondrial Genome Database. http://www.mitomap.org, 2013, and
http://www.ncbi.nlm.nih.gov/pubmed/21935892), and are responsible
for a wide range of syndromes, such as the severe Mitochondrial
Encephalopathy with Lactic Acidosis and Stroke-like episodes (MELAS)
for which no effective treatment is available at present.
Experimental evidence has shown that the detrimental effects
of mt-tRNA point mutations in human cells can be attenuated by
modulating the expression of aminoacyl-tRNA synthetases (aaRSs)
(Park et al, 2008; Rorbach et al, 2008; Li & Guan, 2010; Perli et al,
2012). These are ubiquitously expressed, essential enzymes per-
forming the attachment of amino acids to their cognate tRNA mol-
ecules, the first step of protein synthesis. Depending on the
cellular compartment and the set of tRNAs used as substrates,
aaRSs can be specific to cytoplasm, mitochondria, or, in some
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cases, both. Furthermore, aaRSs are grouped in two classes, based
on their structural and functional properties (Ibba & Soll, 2000;
Antonellis & Green, 2008; Suzuki et al, 2011). Class I aaRSs (spe-
cific for aminoacids Val, Leu, Ile, Met, Cys, Glu, Gln, Tyr, Trp and
Arg) are mostly monomeric and contain a nucleotide-binding cata-
lytic domain with a Rossman fold, made of six parallel b-strands
alternating to a-helices (Li et al, 1992; Martinis & Boniecki, 2010).
They approach the end of the tRNA acceptor helix from the minor
groove side and catalyse the attachment of the aminoacid to the
2′-OH at the 3′-end of the tRNA chain. Class II aaRSs (specific for
amino acids Gly, Ala, Ser, Thr, Asn, Asp, Lys, His, Phe and Pro)
are mostly dimeric or multimeric and contain an anti-parallel b-
sheet flanked by a-helices (Perona et al, 1993) sharing at least
three conserved regions (Cusack et al, 1991; Schimmel, 1991; Del-
arue & Moras, 1993). Class II aaRS’s generally approach the end
of the tRNA from the major groove, attaching the aminoacid to
the 3′-OH. Class I and Class II are further divided into a, b, c sub-
classes, each comprising enzymes sharing sequence, structure and
function similarities.
A role for mt aminoacyl-tRNA synthetases has been established
in human disease (Suzuki et al, 2011), since several of them have
been reported to carry mutations in patients with a spectrum of dif-
ferent clinical phenotypes (Suzuki et al, 2011; Bayat et al, 2012; Elo
et al, 2012; Steenweg et al, 2012). Mutations can affect the mt-
aaRSs catalytic or editing domain (Scheper et al, 2007; Riley et al,
2010; G€otz et al, 2011), the ATP binding site (Elo et al, 2012) or the
mt targeting sequence (Messmer et al, 2011), or may result in
immature, truncated proteins (Edvardson et al, 2007). Severe reduc-
tion in steady-state levels of the corresponding mt-tRNA has been
reported as an associated feature (Edvardson et al, 2007; Belostot-
sky et al, 2011).
The ability of overexpressed cognate mt-aaRS to attenuate the
detrimental effects of mt-tRNA point mutations has been demon-
strated both in yeast and human cell lines (De Luca et al, 2006,
2009; Park et al, 2008; Rorbach et al, 2008; Li & Guan, 2010). In
particular, studies on human cells (Park et al, 2008; Li & Guan,
2010) have shown that overexpression of mt leucyl-tRNA synthetase
(mt-LeuRS) corrects the respiratory chain deficiency of transmito-
chondrial cybrids harbouring the MELAS-associated m.3243A>G
mutation in the mt-tRNALeu(UUR) gene (MTTL1). Likewise, steady-
state levels of mutated mt-tRNAVal were partially restored by over-
expressing the cognate mt valyl-tRNA synthetase (mt-ValRS) in
cybrid cell lines (Rorbach et al, 2008). Recently, we showed that
constitutive high levels of mt isoleucyl-tRNA synthetase (mt-IleRS)
are associated with reduced penetrance of the homoplasmic
m.4277T>C mt-tRNAIle mutation, causing hypertrophic cardiomyo-
pathy. Our in vivo findings were paralleled by results in mutant
transmitochondrial cybrids following overexpression of mt-IleRS
(Perli et al, 2012).
In yeast, the overexpression of either human mt-LeuRS or
mt-ValRS is capable of rescuing the pathological phenotype associ-
ated with human equivalent point mutations in mt-tRNALeu and
mt-tRNAVal. In other words, the expression of either enzyme (both
belonging to Class Ia) rescued the phenotypes determined by muta-
tions in either the cognate or the non-cognate yeast mt-tRNA. This
cross-activity was proposed to reside in regions of mt-LeuRS and
mt-ValRS involved in the interactions with tRNA molecules (Monta-
nari et al, 2010).
More recently, a region necessary and sufficient to rescue the
defective phenotype of human-equivalent mutations in yeast
mt-tRNALeu, mt-tRNAVal and mt-tRNAIle has been identified in
the carboxy-terminal domain of yeast mt-LeuRS (Francisci et al, 2011).
In the present study, we extended the results obtained in the
yeast model to human transmitochondrial cybrid cells (herein
named cybrids), by showing the interchangeable ability of three
human mt-aaRS, namely mt-ValRS, mt-LeuRS and mt-IleRS, to sup-
press the mitochondrial functional defects associated with patho-
genic homoplasmic mutations in mt-tRNAIle gene (MTTI).
Importantly, we also demonstrate that phenotype rescue can be
obtained for either “mild” or “severe” mutations by overexpressing
the isolated carboxy-terminal domain of human mt-LeuRS.
Results
Pathological phenotype of m.4277T>C and m.4300A>G MTTI
mutant cybrids
We used previously established osteosarcoma-derived (143B.TK-)
cybrid cell lines from patients (Perli et al, 2012) and controls
(Ghelli et al, 2009; Pello et al, 2008; generous gift from Dr Mon-
ica Montopoli and Dr Valerio Carelli) (supplementary Table S1).
Both the m.4277T>C and m.4300A>G were previously confirmed
as being homoplasmic in all cell lines (Perli et al, 2012). To
Figure 1. The ability of overexpressed human mt-ValRS and mt-LeuRS to correct mt dysfunction of mutant cybrids carrying the m.4277T>C and m.4300A>G
mutations in MTTI gene is interchangeable.
A Viability of mock, LeuRS and ValRS transformants (M, pLARS2 and pVARS2) evaluated after 48 h incubation in galactose medium. The number of viable cells in
galactose is normalized to the number of viable cells in glucose at the same time point. Results are the mean  s.e.m. of triplicate transfection experiments on
n = 2 WT, n = 2 m.4277T>C and n = 2 m.4300A>G cell lines.
B Apoptotic cell death of M, pLARS2 and pVARS2 evaluated after 24 h incubation in galactose medium and expressed as a ratio between the percentage of apoptotic
cells in galactose and in glucose medium. Results are the mean  s.e.m. of at least duplicate transfection experiments on n = 2 WT, n=2 m.4277T>C and
n = 2 m.4300A>G cell lines.
C Relative expression levels of LARS2 and VARS2 genes in trasformants cybrids with respect to HPRT1 gene. Gene expression levels are normalized to the gene
expression level of the respective mock (indicated by the line).
D Representative images showing expression levels of mt-LeuRS and mt-ValRS in transformant cybrids carrying the m.4277T>C mutation. Top panels:
immunofluorescence of M and pLARS2 with a specific anti mt-LeuRS antibody (HPA035951). Bottom panels: M and pVARS2 stained with an anti mt-ValRS specific
antibody (15776-1-AP) (see Materials and Methods). Nuclei are stained with DAPI. (Scale bar: 15 lm).
Data information: *P < 0.05, **P < 0.01, ***P < 0.001; § P < 0.05, §§ P < 0.001, §§§ P < 0.0001 for mutant versus WT mock cells (ANOVA test).
▸
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unravel the pathological phenotype, mutant cybrids were grown
in glucose-free medium supplemented with galactose (galactose
medium), a condition forcing cells to rely on the mt respiratory
chain for ATP synthesis. As previously reported, in this condition
the selected mutant cybrids clones consistently show a significant
reduction in oxygen consumption and viability, the latter due to
increased apoptotic death (Perli et al, 2012). As expected, cybrids
transiently transfected with mock vectors (see Materials and
A
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C
Figure 1.
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Methods) retained the pathological phenotype (supplementary
Fig S1).
Phenotype correction of MTTI cybrids by overexpressing non-
cognate human mt-ValRS and mt-LeuRS
We previously showed that transient overexpression of cognate
mt-IleRS determines a 1.5-fold increase in the viability of m.4277T>C
MTTI mutant cybrids grown in galactose medium (Perli et al, 2012).
We have obtained similar results with cybrids carrying the homo-
plasmic m.4300A>G MTTI mutation (supplementary Fig S2). We
now show that overexpression of non-cognate mt-ValRS and
mt-LeuRS (VARS2 and LARS2 genes, respectively) increases the
viability of both cybrid lines after 48 h of galactose incubation (up
to 2-fold as compared to mock transformants) and decreases apopto-
tic cell death after 24 h (up to 2.5-fold decrease as compared to
mock transformants) (Fig 1A and B).
For each experiment, we measured the transfection efficiency by
quantitative real-time PCR (Fig 1C). We found a comparable
increase in mRNA expression for mt-LeuRS (mean: +2-fold, range:
1.92–2.17) and mt-ValRS (mean: +2-fold, range: 1.74–2.31) transfor-
mants, associated with increased levels of the corresponding
proteins, evaluated by immunofluorescence (Fig 1D). Furthermore
mt-aaRSs overexpression had no significant effect on viability of
wild-type (WT) cybrids (Fig 1A and B).
The carboxy-terminal domain of human mt-LeuRS is necessary
and sufficient to correct the phenotype of MTTI mutant cybrids
Phenotype correction of MTTI cybrids by non-cognate mt-aaRS
favours the hypothesis that the catalytic function of these
enzymes is not primarily involved in the rescuing activity. Based
on previous results in yeast, we decided to test the effect of the
non- catalytic carboxy-terminal domain of human mt-LeuRS in
mutant cybrids. We transiently transfected cybrids with a vector
carrying a peptide composed of the 67 C-terminal residues (from
amino acid 837 to 903) of human mt-LeuRS (herein named
Cterm, see Materials and Methods). Similar to yeast (Francisci
et al, 2011), galactose-grown transfected mutant cybrids
displayed increased viability after 48 h of galactose medium incu-
bation (+2.2 fold relative to mock transformants) and decreased
apoptotic cell death after 24 h (up to +2.5) (Fig 2A and B). To
investigate whether increased cell viability was indeed related to
improved mitochondrial bioenergetics, we measured oxygen con-
sumption rate in transfected cybrids. Using microscale oxygraphy
(Invernizzi et al, 2012) we clearly demonstrated a significant
increase in the maximal respiration rate (MRR) in Cterm trans-
fected mutant cybrids as compared to mock (Fig 2C). Cterm
overexpression had no effect on the viability or MRR of WT
cybrids.
Finally, overexpression of a human mt-LeuRS variant lacking the
C-term domain (DCterm) failed to significantly increase cell viability
and oxygen consumption rate (Fig 2A and B). Again, we measured
transfection efficiency in each experiment (Fig 2D). The mRNA
expression increased in both Cterm (mean: 2.1-fold increase, range:
1.74–2.63) and DCterm transformants (mean: 1.8-fold increase,
range: 1.82–1.86), paralleled by an increase of the corresponding
proteins (Fig 2E).
The carboxy-terminal domain of human mt-LeuRS is able to
rescue the phenotype of m.3243A>G MTTL1 mutant cybrids
In order to challenge these results against a severe MTT mutation,
we transiently expressed Cterm, DCterm and full-length mt-LeuRS
protein in cybrid cell lines bearing homoplasmic levels of the
m.3243A>G “MELAS” mutation in MTTL1 (supplementary Table
S1). The assessment of m.3243A>G mutation load in cybrids was
performed by quantitative pyrosequencing (supplementary Fig S3).
As previously demonstrated (King et al, 1992) cells carrying high
levels of this mutation show severe reduction of the respiratory
chain activity and impaired cell growth. In fact, mutant cybrids
grown in standard galactose medium undergo massive death within
12 h (see supplementary Fig S4). For this reason we added non-
dialyzed FBS to the culture medium (herein galactose permissive
medium, GPM) to perform viability experiments. Cybrids transiently
overexpressing Cterm displayed increased cell viability after 48 h of
incubation in GPM (up to 4 fold as compared to mock transfor-
mants) and decreased apoptosis after 24 h (up to 3.5 fold decrease
as compared to mock transformants) (Fig 3A, B and supplementary
Fig S5). Again, Cterm overexpression did not impact on viability
and respiration of WT cybrids.
Interestingly, transfection with the DCterm also resulted in a
partial phenotype rescuing, suggesting that different regions of
mt-LeuRS can contribute to correct the defect associated with the
mutated mt-tRNALeu(UUR). In line with previous observations (Park
et al, 2008; Li & Guan, 2010) cybrids transfected with the whole
enzyme showed significant phenotype improvement (Fig 3A and B).
To assess whether phenotype rescuing reflected an improve-
ment in mitochondrial energetics we evaluated the rate of oxygen
consumption of mutant cybrids transfected with the isolated
Cterm domain, DCterm or whole enzyme as compared to cybrids
transfected with the empty vector. Whilst all three transfected lines
showed an increase in oxygen consumption rate the improvement
was significant only for Cterm transformants (Fig 3C). Transfec-
tion efficiency was comparable in the three transformants (Fig 3D
and E).
We next investigated whether transfection with the Cterm
domain had a direct consequence on the mutated mt-tRNALeu(UUR)
in vivo. We assessed the steady-state levels of deacylated
mt-tRNALeu(UUR) by high resolution northern blot analysis in WT
and m.3243A>G MTTL1 mutant cybrids transiently transfected with
the whole LeuRS enzyme, the Cterm domain and the MTS-Cterm
domain. Values were normalized for 5S rRNA. As expected, the
steady-state levels of mutated mt-tRNALeu(UUR) were reduced by
~50% relative to WT. Transient overexpression of the three con-
structs did not result in a detectable increase of the mutated
mt-tRNALeu(UUR) steady-state levels (supplementary Fig S6).
Taken together, these results demonstrate that the Cterm
domain can rescue the defective OXPHOS phenotype of MELAS
cybrids, being in fact more efficient than the full-length mt-LeuRS
protein. Intriguingly, functional rescue is not paralleled by a
detectable increase in steady-state levels of the mutated tRNA.
The Cterm domain of human mt-LeuRS localizes to mitochondria
To test whether the rescuing ability of the Cterm is associated with
mitochondrial localization, we immunovisualized the peptide both
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in m.3243A>G transformants and mock, by immunofluorescence
with a specific antibody (see Materials and Methods). We also pro-
duced a recombinant peptide, composed of the mitochondrial target-
ing sequence (MTS) of Neurospora crassa F0-ATPase subunit 9
precursor (Westermann & Neupert, 2000) fused in frame with the
Cterm N-terminus (MTS-Cterm). As shown in Fig 4A, the Cterm-
specific immunofluorescence (IF) pattern decorates the mt network
and perfectly matches the pattern of MTS-Cterm. Since the antibody
used for our IF experiments is specific for a Cterm epitope, we were
unable to distinguish endogenous mt-LeuRS from the overexpressed
Cterm peptides. However, IF staining intensity in both Cterm and
MTS-Cterm transformants was clearly higher than in mock, consis-
tent with overexpression of the peptides.
To corroborate the immunofluorescence findings, we performed
mitochondrial import assay of radiolabeled in vitro-translated Cterm
and MTS-Cterm. As shown in Fig 4B, the Cterm was imported in a
A
C
E
D
M pCterm
pΔCtermM
B
Figure 2. The Cterm domain is both necessary and sufficient to improve cell viability and mitochondrial bioenergetics of cybrids carrying the m.4277T>C and
m.4300A>G mutations in MTTI gene.
A Viability of mock, DCterm and Cterm transformants (M, pDCterm and pCterm) evaluated after 48 h incubation in galactose medium. The number of viable cells in
galactose medium is normalized to the number of viable cells in glucose at the same time point. Results are the mean  s.e.m. of triplicate transfection
experiments on n = 2 WT, n = 2 m.4277T>C and n = 2 m.4300A>G cell lines.
B Apoptotic cell death of M, pDCterm and pCterm evaluated after 24 h incubation in galactose medium and expressed as ratio between the percentage of apoptotic
cells in galactose and in glucose medium. Results are the mean  s.e.m. of at least duplicate transfection experiments on n = 2 WT, n = 2 m.4277T>C and
n = 2 m.4300A>G cell lines.
C Maximal respiration rate (MRR) measured in M, pDCterm and pCterm. Values are expressed as ratio of MRR in galactose and in glucose medium. MRR of pCterm is
increased by 0.3-fold for m.4277T>C and 0.8 fold for m.4300A>G cybrids as compared to their respective mocks. Results are the mean  s.e.m. of triplicate
transfection experiments on n = 1 WT, n = 1 m.4277T>C and n = 1 m.4300A>G cell lines.
D Relative expression levels of DCterm and Cterm in trasformant cybrids with respect to HPRT1 gene. Gene expression levels of DCterm and Cterm are normalized to
the gene expression level of the respective mock (indicated by the line).
E Representative images showing the expression levels of DCterm and Cterm in transformant cybrids carrying the m.4277T>C mutation. Top panels:
immunofluorescence of M and pDCterm stained with a specific anti-mt-LeuRS antibody (HPA035951). Bottom panels: M and pCterm stained with an anti-mt-LeuRS
specific for C-terminal region (17097-1-AP) (see Materials and Methods). Nuclei are stained with DAPI. (Scale bar: 15 lm).
Data information: *P < 0.05, **P < 0.01, ***P < 0.001; § P < 0.05, §§ P < 0.001, §§§ P < 0.0001 for mutant versus WT mock cells (ANOVA test).
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membrane potential-dependent manner, with an efficiency of ~30%.
The presence of the MTS improved the efficiency of mitochondrial
import up to ~54%. Following trypsin digestion only the smaller
band corresponding to the isolated Cterm was detectable (Fig 4B,
arrowhead), consistent with MTS cleavage after translocation into
the organelle.
Interestingly, the relative increase in mitochondrial import effi-
ciency does not result in higher rescuing activity of the MTS-Cterm.
In fact, overexpression of the Cterm --- either with or without the
MTS --- produced comparable effects on viability, apoptotic rate,
and oxygen consumption of MELAS cybrids (Fig 5).
The observation that the LeuRS Cterm domain can be imported
into mitochondria is not surprising. In fact, for a large fraction of
proteins with mt localization a canonical MTS has not been identi-
fied (Bolender et al, 2008; Li et al, 2010). Furthermore, sequence
analysis highlighted that both human and yeast C-terminal domains
B
C D
E
M
M
pLARS2 pΔCterm
pCterm
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Figure 3. The Cterm domain is able to improve cell viability andmitochondrial bioenergetics of cybrids carrying the severe 3243A>Gmutation inMTTL1 gene..
A Viability of mock, LARS2, DCterm and Cterm transformants (M, pLARS2, pDCterm and pCterm) evaluated after 48 h incubation in galactose-permissive medium
(GPM). The number of viable cells in this condition is normalized to the number of viable cells in glucose at the same time point. Results are the mean  s.e.m. of
triplicate transfection experiments on n = 1 WT and n = 1 m.3243A>G cell lines.
B Apoptotic cell death of M, pLARS2, pDCterm and pCterm evaluated after 24 h incubation in GPM and expressed as ratio between the percentage of apoptotic cells
in GPM and in glucose medium. Representative scatter plots are shown in supplementary Fig S4. Results are the mean  s.e.m. of triplicate transfection
experiments on n = 1 WT and n = 1 m.3243A>G cell lines.
C Rate of oxygen consumption measured in M, pLARS2, pDCterm and pCterm maintained in glucose medium. Results are the mean  s.e.m. of triplicate transfection
experiments on n = 2 WT and n = 1 m.3243A>G cell lines.
D Relative expression levels of LARS2, DCterm and Cterm in trasformants cybrids with respect to HPRT1 gene. Gene expression levels are normalized to the gene
expression level of the respective mock (indicated by the line).
E Representative images showing the expression levels of mt-LeuRS, DCterm and Cterm in transformant cybrids carrying the m.3243A>G mutation. Top panels:
immunofluorescence of M, pLARS2and pDCterm stained with a specific anti mt-LeuRS antibody (HPA035951). Bottom panels: M and pCterm stained with an anti
mt-LeuRS specific for C-terminal region (17097-1-AP) (see Materials and Methods). Nuclei are stained with DAPI. (Scale bar: 15 lm).
Data information: *P < 0.05, ** P < 0.01, *** P < 0.001; §§ P < 0.01, §§§ P < 0.0001 for mutant versus WT mock cells (ANOVA test).
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have a favourable positive/negative residues ratio (1.8 and 3.8,
respectively), which is higher than in the rest of the protein (0.96
for both human and yeast mt-LeuRS) and similar to that of the
N-terminal MTS of the whole enzymes (Zagorski et al, 1991; Bullard
et al, 2000). To investigate the putative spatial location of the
positively charged residues we built molecular models of human
and yeast Cterm domains. Model inspection showed that, for both
domains, positive residues that are distant in the amino acid
sequences cluster in the three-dimensional structure to form posi-
tively charged patches (supplementary Fig S7).
Figure 4. The Cterm domain targets to mitochondria..
A Double immunofluorescence stain of mock, Cterm and MTS-Cterm transformants (M, pCterm, pMTS-Cterm) showing colocalization of the antibody against the Cterm
region of mt-LeuRS and the antibody against mt extract antigens. Overexpression of the Cterm is highlighted by a stronger mitochondrial immunostaining, as
compared to endogenous levels in mock. Highly efficiently transformed cells are marked by an asterisk. Overlap is shown in yellow. Nuclei are stained with DAPI.
Cells were examined and imaged with an Olympus IX50 fluorescence microscope. (Scale bar: 15 lm).
B Import assay of in vitro synthesised human peptides Cterm and MTS-Cterm. Incubation of human proteins with isolated rat liver mitochondria in the absence
(control) or presence of an uncoupling agent (FCCP) was followed by treatment with either 100 lg/ml trypsin or trypsin plus Triton X-100 and resolved in 18% Tris-
glycine SDS–PAGE. The empty vector (M) where the human peptides were cloned was used as a negative control. Same portions of the gels are shown for
comparison purposes and TnT reactions are also loaded as a control in each case. The percentage of in vitro synthetized peptide able to bind to the mitochondria
(mitochondrial binding) and the percentage of imported peptide (import efficiency) are also shown for each assay.
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The Cterm domain of human mt-LeuRS directly interacts with
mt-tRNALeu(UUR) and mt-tRNAIle in vitro
We tested the ability of Cterm to interact directly with human
mt-tRNALeu(UUR) and mt-tRNAIle by Surface Plasmon Resonance
(SPR). The 5′-biotinylated mt-tRNALeu(UUR) and 5′-biotinylated mt-
tRNAIle were immobilized on the streptavidin-containing surface of
two different SPR sensorchips, and allowed to interact with different
concentrations of a purified recombinant construct comprising
glutathione S-transferase (GST) protein fused in frame with the
Cterm domain (GST-Cterm) (Fig 6A). We found that the affinity of
GST-Cterm interaction for 5′-biotinylated mt-tRNALeu(UUR) is high,
the KD of the complex being about 0.6 lM (Fig 6C). In particular,
the dissociation rate is very low in our experimental conditions,
indicating high stability of the complex. The same experiments were
performed with GST alone, at the same concentrations used for
GST-Cterm in the experiment in Fig 6A, as a negative control. As
expected, GST binding to tRNA was negligible (about 20%, supple-
mentary Fig S8). The affinity of GST-Cterm for 5′-biotinylated
mt-tRNAIle is lower than for 5′-biotinylated mt-tRNALeu(UUR), the KD
of the complex being about 2.5 lM (Fig 6B and C). The same exper-
iments, performed with GST alone, showed that GST binding to
tRNAIle was negligible (about 15%, supplementary Fig S8).
Discussion
In the present study we show that three human mt-aaRS, namely
mt-LeuRS, mt-ValRS, and mt-IleRS, are able to ameliorate the mt
defects associated with two mutations in mt-tRNAIle (MTTI). Impor-
tantly, we show that phenotype rescuing is obtained both for these
“mild” mutations and for the “severe” m.3243A>G mutation in
Figure 5. Rescuing effect of Cterm and MTS-Cterm on the m.3243A>G MTTL1 mutant cybrids defective phenotype.
A Viability of pcDNA5/FRT/TO Cterm (pCterm) and pcDNA3.2 MTS-Cterm (pMTS-Cterm) transformants after 24 h incubation in galactose permissive medium (GPM).
The number of viable cells in GPM is normalized to the number of viable cells in glucose at the same time point.
B Apoptotic cell death after 24 h incubation in GPM and expressed as a ratio between the percentage of apoptotic cells in GPM and in glucose medium.
C Rate of oxygen consumption of pCterm and pMTS-Cterm transformants maintained in glucose medium. pCterm and pMTS-Cterm transformants are compared with
their respective mock (M).
D Relative expression levels of Cterm and MTS-Cterm with respect to HPRT1 gene. Gene expression levels are normalized to the gene expression level of the respective
M. Data represent mean of three replicates on one mutant and one WT cell line.
Data information: *P < 0.05, **P < 0.01, ***P < 0.001; §P < 0,05, §§§P < 0.0001 for mutant versus WT mock cells (ANOVA test)
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MTTL1 gene, by overexpressing the carboxy-terminal domain of
human mt-LeuRS (Cterm). The m.4277T>C and m.4300A>G MTTI
gene mutations cause isolated cardiomyopathy and are found at
homoplasmic levels (Taylor et al, 2003; Perli et al, 2012), whereas
the m.3243A>G MTTL1 gene mutation is heteroplasmic, and can be
associated with severe biochemical and clinical phenotypes, such as
those ascribed to MELAS (Kaufmann et al, 2011) at high mutation
loads. Besides the typical MELAS phenotype, the m.3243A>G muta-
tion has been associated with a wide spectrum of clinical manifesta-
tions, including maternally-inherited diabetes and deafness (MIDD),
partly dictated by the level of m.3243A>G heteroplasmy, and its fre-
quency in some populations is higher than previously thought
(Manwaring et al, 2007).
Remarkably, overexpression of Cterm was sufficient to improve
both viability and bioenergetic proficiency of cybrids bearing muta-
tions in either cognate or non-cognate mt-tRNAs. Moreover, the
Cterm had a higher rescuing activity than the whole enzyme towards
all of the tested mutations. Conversely, the ΔCterm mt-LeuRS variant
had negligible or no effect on the phenotype of cybrids bearing muta-
tions in cognate and non-cognate mt-tRNAs, respectively.
Consistent with the observed functional effect of the Cterm on
mutant cybrids, we show that this short (67 residues long) domain
is imported into mitochondria. In the absence of a typical N-termi-
nal MTS, the mt localization of overexpressed human Cterm demon-
strated in this work may be due to the predominance of positive
over negative amino-acid residues in the sequence (Bullard et al,
2000; Neupert & Hermann, 2007), and to the spatial clustering of
positive residues, as suggested by the three-dimensional homology
model of the Cterm.
Interestingly, adding a canonical MTS does not improve the res-
cuing by the Cterm, despite the observed enhancement in mitochon-
drial import efficiency.
Taken together, our results sustain the hypothesis that human
mt-LeuRS Cterm can be used to correct mt dysfunctions caused by
mutations in mt-tRNA genes. Our findings extend to human the
results previously obtained in the yeast Saccharomyces cerevisiae
(De Luca et al, 2009; Montanari et al, 2010; Francisci et al, 2011).
Since our results are relevant for potential therapeutic applica-
tions, an investigation of the mechanisms underlying the rescuing
activity of the Cterm is called for. In the three-dimensional struc-
tures of Thermus thermophilus (Tukalo et al, 2005) and Escherichia
coli (Palencia et al, 2012) LeuRS–tRNALeu complexes determined by
X-ray crystallography (Protein Data Bank (PDB) IDs: 2BTE and
4AS1, respectively), the Cterm domain of LeuRS interacts with the
elbow of the L-shaped tRNA, stabilizing the complex (Hsu & Marti-
nis, 2008; Hu et al, 2013). Based on these observations, we previ-
ously proposed that the Cterm of yeast LeuRS (NAM2 gene) may act
as a chaperone (Francisci et al, 2011), by directly interacting with
the mutant mt-tRNALeu and stabilizing a conformation suitable to
react with the mt-LeuRS and/or less amenable to degradation.
Accordingly, we have shown here that Cterm is able to directly and
specifically interact with human mt-tRNALeu(UUR) in vitro, with high
affinity and stability. Consistent with its rescuing activity in cybrids
bearing the m.4300A>G and m.4277T>C mutations, the Cterm
interacted in vitro with the non-cognate human mt-tRNAIle, although
with lower affinity. These results strongly suggest that functional
rescuing of mt-tRNALeu(UUR) and mt-tRNAIle defects is mediated by
physical interactions of LeuRS Cterm with mutant tRNAs.
At variance with previous reports (Park et al, 2008; Rorbach
et al, 2008; Li & Guan, 2010) and the accompanying paper, we did
not detect an increase of mutant mt-tRNALeu(UUR) steady-state levels
upon transient overexpression of either Cterm or the whole LeuRS
enzyme, despite a significant increase in cell viability and mitochon-
drial respiration. This finding suggests that the effect of the Cterm is
mainly to improve the function of the mutant mt-tRNALeu(UUR)
rather than preventing it from degradation. As a consequence, mt
translation and OXPHOS would improve, and apoptosis would be
prevented. It is also possible that on a longer timescale, this effect
may lead to an increase of the steady-state levels of mt-tRNA, as
reported elsewhere, that was not observed in the transient, “acute”
experiment shown here.
A
B
C
Figure 6. The Cterm peptide directly interacts with human mt-tRNALeu
(UUR) and mt-tRNAIle.
A Interaction of GST-Cterm with 5′-biotinylated human mt-tRNALeu(UUR)
immobilized on a streptavidin-coated sensor chip, measured by Surface
Plasmon Resonance experiments. Sensorgrams were obtained using 5′-
biotinylated mt-tRNALeu(UUR) as ligand and GST-Cterm (concentration: 10,
20, 40, 80, 120, 400, 600 nM, 1.2, 2.5, 5.0 lM) as analyte.
B Interaction of GST-Cterm with 5′-biotinylated mt-tRNAIle immobilized on a
streptavidin-coated sensorchip, measured by Surface Plasmon Resonance
experiments. Sensorgrams were obtained using 5′-biotinylated mt-tRNAIle
as ligand and GST-Cterm (concentration: 150, 300, 600 nM, 1.2, 2.5, 5.0, 10,
20, 30 lM) as analyte.
C Scatchard plot of the sensorgrams. The resulting KD is 0.6 lM for
5′-biotinylated mt-tRNALeu(UUR) (●) and 2.5 lM for 5′-biotinylated
mt-tRNAIle (○).
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We also demonstrate that the catalytic activity of human
mt-LeuRS is dispensable for the rescuing effect, since the latter is
carried out by the short, catalytically incompetent, Cterm domain,
in agreement with previously obtained data in yeast model (De Luca
et al, 2009; Francisci et al, 2011).
We propose that the Cterm acts as a chaperone by direct physical
contact with the mutated mt-tRNA in vivo, helping it to maintain
the conformation suitable to proficiently interact with its cognate
aminoacyl-tRNA synthetase or other molecular partners.
This hypothesis is in agreement with the higher rescuing activity
displayed by the Cterm relative to the whole enzyme, since the
reduced steric hindrance of the former is likely to reduce the interfer-
ence of the tRNA interactions with (a) the cognate aaRS, or (b) other
molecular partners, for example the ribosome. For instance, in silico
analysis of T. thermophilus tRNALeu-LeuRS complex, and tRNAPhe-
mt ribosome complex suggest that only free tRNAs can efficiently
get access to the ribosome (Selmer et al, 2006; PDB ID: 2J00).
The ability of the short Cterm to rescue both mild and severe
defects associated with cognate and non-cognate mt-tRNA muta-
tions opens new perspectives for treatment of human diseases asso-
ciated with mt-tRNA mutations. For instance, adeno-associated
virus-mediated targeting could be exploited to express the isolated
Cterm in vivo. The efficacy and safety of this approach have been
demonstrated both in human (Nathwani et al, 2011) and in animal
models of genetic disease (Di Meo et al, 2012).
Alternatively, the recent demonstration of the rescuing activity
obtained by overexpressing the short b30–31 sequence of the human
Cterm in the yeast model (Francisci et al, 2011) suggests that Cterm-
derived peptides may be used as therapeutic agents, provided that
suitable agents for mitochondria targeting are employed to deliver
them to their subcellular destination. Cterm peptides may even
prompt the development of non-peptide organic molecules, especially
if the rescuing activity can be further restricted to smaller regions.
In light of a broader application of this therapeutic approach, fur-
ther experiments are advised to test the effect of mt-LeuRS Cterm
and/or smaller peptides thereof on further mutations in mt-tRNAs
aminoacylated by class I or II aaRS. In parallel, it will be worth
investigating the structural determinants of the cross-rescuing activ-
ity of IleRS and ValRS and whether additional aaRSs are endowed
with the same ability. In this framework, it should be noted that in
the yeast model, while overexpression of whole mt-IleRS rescues
the defects due to mutations in both mt tRNAIle and tRNALeu, the
carboxy-terminal domain of IleRS --- contrary to the Cterm of mt-
LeuRS --- does not rescue either mutant (supplementary Fig S9).
Accordingly, sequence and structure analyses indicate that there is
no obvious homology between the carboxy-terminal domains of
LeuRS and IleRS (supplementary Fig S10 A, B and C), suggesting
that the determinants of the cross-rescuing activity of different
aaRSs are likely to reside in different enzyme regions.
Materials and Methods
Cell culture
Cybrids were cultured in Dulbecco’s modified Eagle’s medium
(DMEM), supplemented with 4.5 g/l D-glucose, 10% fetal bovine
serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml
streptomycin (referred to as glucose medium) in a humidified
atmosphere of 95% air and 5% CO2 at 37°C. For a subset of experi-
ments cybrids were growth in glucose-free DMEM, supplemented
with 5 mM galactose, 110 mg/ml sodium pyruvate and 10% dia-
lyzed FBS (dFBS) (referred to as galactose medium). For a subset of
experiments m.3243A>G cybrids were grown in glucose-free DMEM,
supplemented with 5 mM galactose, 110 mg/ml sodium pyruvate
and 10% FBS (referred to as permissive galactose medium).
Assessment of m.3243A>G mutation load
The assessment of m.3243A>G mutation load was performed by
quantitative pyrosequencing. Pyromark Assay Design Software v.2.0
(Qiagen, Hamburg, Germany) was used to design locus-specific PCR
and pyrosequencing primers. A 211 bp PCR product spanning the
m.3243 nucleotide was amplified using a biotinylated forward pri-
mer (nt 3143–3163) and a reverse primer (nt 3353–3331). Pyrose-
quencing was carried out on the Pyromark Q24 platform according
to the manufacturer’s instructions, using a mutation-specific reverse
primer (nt 3258–3244). Levels of m.3243A>G heteroplasmy were
determined using Pyromark Q24 software, which directly compares
the relevant peak heights of both WT and mutant mtDNA at this
site.
Plasmid construction
Standard protocols were used for E. coli transformation as well as
plasmid preparations (Sambrook et al, 1989). The pcDNA5/FRT/TO
VARS2 plasmid (pVARS2) was kindly provided by Prof. R.N.
Lightowlers (Rorbach et al, 2008). The human LARS2 gene cDNA
(consensus CDS 2728.1) was subcloned from pYES2.1/V5-His-TOPO
(Montanari et al, 2010) into BamHI/XhoI restriction sites of the
pcDNA5/FRT/TO plasmid (InvitrogenTM, Life Technologies Italia,
MB, Italy) (pLARS2). The LARS2 cDNA deleted of the entire Cterm
domain (from residue 837 to 903) was amplified and cloned into the
BamHI/XhoI restriction sites of the pcDNA5/FRT/TO (pDCterm).
Both constructs were kindly provided by Prof. R.N. Lightowlers. To
produce the pcDNA5/FRT/TO Cterm plasmid (pCterm), the frag-
ment of the LARS2 cDNA from 2509 to 2712 bp was amplified from
pLARS2 using BamHICtermLARS2+ (5′- CGGGATCCCGATGGAG
GTTGTCCAGATGGCAGTTC- 3′), that contains the additional ATG
codon (in bold) and BamHICtermLARS2- (5′- CGGGATCCCGTCAA
TCTTGCACCAGGAAGTTG- 3′) that contains the STOP codon (in
bold). In each primer the BamHI restriction site sequence is under-
lined. The PCR product was cloned into the BamHI restriction site of
the plasmid. The final cloned construct contains the initiator Met
codon and the 67 terminal amino acids (from residue 837 to 903) of
human mt LeuRS. The Cterm domain from human LARS2 gene,
fused at 5′ with the residues 1–69 of Neurospora crassa Fo-ATPase
subunit 9 precursor (NCBI accession number: XP_959894) and at 3′
with GFP (spaced by a 9 residues linker: LEMESDESG) was cloned
into pTUNE plasmid (LifeTechnologies, Carlsbad, CA, USA). Using
the latter plasmid as template and the primers listed below, ampli-
con containing MTS-Cterm and Cterm were obtained and subcloned
into pcDNA3.2-TOPO plasmid (InvitrogenTM, Life Technologies, Ita-
lia, MB, Italy) (pMTS-Cterm and p3.2Cterm).
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MTS pcDNA3.2 Fw: 5′-CACCATGGCGAGTACTCGGG-3′; Cterm
pcDNA3.2 Fw: 5′-CACCATGGAGGTTGTCCAGATGGCA-3′; Cterm
Rc: 5′-TCATCAATCTTGCACCAGGA-3′.
IARS2 was cloned in pTUNE vector as described in Perli et al
(2012) (pIARS2).
Transient transfections
Cybrids were plated in 60-mm dishes, incubated in glucose medium
for 24 h, and then transfected with 2 lg of the full or empty vector
by using Turbofectin 8 (Origene Technologies, Inc., Rockville, MD,
USA) according to the manufacturer’s protocol.
Six hours after transfection, 2 mM tetracycline (Sigma, St Louis,
MO, USA) was added to the medium of pcDNA5/FRT/TO transfor-
mants while 150 lM isopropyl-b-D-1-thiogalactopyranoside (IPTG,
Sigma) was added to the medium of pTUNE transformants for vec-
tor induction. All the media used for the successive experiments
were supplemented with constant concentrations of these inducers.
Evaluation of transient transfection efficiency by quantitative
real-time PCR
About 48 h after transfection total RNA was isolated from trans-
fected cells using SV Total RNA isolation kit (Promega, Fitch-
burg, WI, USA), measured with a NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies, Wilmington, DE,
USA), and then 0.1–1 mg were reverse-transcribed to cDNA
using random hexamer primers. To assess the relative expression
of IARS2, VARS2, LARS2 and Cterm, we used TaqMan probe
chemistry by means of inventoried and custom FAM-labeled Taq-
Man MGB probes (Applied Biosystems Warrington, UK; supple-
mentary Table S2), according to the manufacturer’s instructions.
In all samples, the relative expression of each target gene was
evaluated with respect to average of controls (mock sample)
using the comparative threshold cycle (DCt) method. All values
were normalized for the housekeeper hypoxanthine phosphoribo-
syltransferase 1 (HPRT1).
Immunofluorescence and co-localization experiments
About 48 h after transfection cells were plated on cover slips,
fixed with 4% formaldehyde freshly prepared from paraformalde-
hyde in PBS (pH 7.4) with 0.1% Triton X-100. The following pri-
mary antibodies were used: rabbit polyclonal antibody anti-mt-
LeuRS (HPA035951, ATLAS antibodies, AlbaNova University Cen-
ter, Stockholm, Sweden) specific for the region spanning the mt-
LeuRS catalytic core and anticodon binding domains (NCBI refer-
ence sequence NP_056155.1); rabbit polyclonal antibody specific
for the Cterm domain of human mt-LeuRS (antigen peptide region
554-903, 17097-1-AP, ProteinTech group, Chicago, IL, USA) and
anti-mt- ValRS (15776-1-AP, ProteinTech group, Chicago, IL,
USA); mouse monoclonal antibody anti-mitochondria extract clone
MTC (UCS Diagnostic, Morlupo, Italy). Primary antibodies were
visualized using secondary FITC- and Cy3-conjugated antibodies
(Jackson Laboratories, Bar Harbor, ME, USA). The cells were
examined and imaged with an Olympus IX50 Fluorescence micro-
scope.
Cell proliferation assay
To test growth capability, transformed cells were maintained in
glucose medium for 24 h and then harvested and seeded at a constant
number of cells (30 × 104) in 60-mm dishes in glucose, galactose or
GPM. Cell viability was measured by the Trypan blue dye exclusion
assay. Cells were harvested after 24/48 h with 0.25% trypsin and
0.2% EDTA, washed, suspended in PBS in the presence of Trypan
blue solution (Sigma) at a 1:1 ratio, and counted using a haemocytom-
eter. For each time point, the number of viable cells in galactose was
expressed as a percentage of the number of cells in glucose.
Rate of apoptosis by flow cytometer
To test the rate of apoptosis transformed cells were maintained in
glucose medium for 24 h and then harvested and seeded at 0.5–
1 × 106 in glucose, galactose or GPM for 24 h. Cells were washed
and harvested in Binding Buffer 1X (BD Biosciences, Franklin Lakes,
NJ, USA) by scraping to minimize potentially high annexin V back-
ground levels in adherent cells. Transfected cells were stained with
APC-conjugated annexin V (BD Biosciences) and analysed on a
FACS-Calibur flow cytometer (BD Biosciences) (Barbarulo et al,
2011).
Respirometry assay
Maximum respiration rate (MRR) of m.4300A>G and m.4277T>C
cybrids was measured with a XF96 Extracellular Flux Analyzer
(Seahorse Bioscience, Billerica, MA, USA).
After transfection control and mutant m.4300A>G and
m.4277T>C cybrids were maintained in glucose medium for 24 h
then harvested and seeded in 8 wells of a XF 96-well cell culture mi-
croplate (Seahorse Bioscience) at a density of 10–15 × 103 cells/well
in 200 ll of medium. After incubation for 12 h at 37°C in 5% CO2
atmosphere, cells were either maintained in glucose medium or
switched to galactose medium for 12 h. The growth medium was
replaced with 180 ll of bicarbonate-free DMEM pre-warmed at 37°C
for 30 min before starting the assay procedure. Maximum respiration
rate (MRR) was assayed as previously described (Invernizzi et al,
2012). Data were expressed as pmol of O2 per minute and normal-
ized by cell number measured by the CyQUANT Cell proliferation kit
(InvitrogenTM, Life Technologies), which is based on a fluorochrome
binding to nucleic acids. Fluorescence was measured in a microplate
luminometer with excitation wavelength at 485  10 nm and emis-
sion detection wavelength at 530  12.5 nm.
The rate of oxygen consumption of cybrids bearing the
m.3243A>G mutation was evaluated with Clark type oxygen elec-
trode (Hansatech Instruments, Norfolk, UK). After transfection con-
trol and mutant cybrids were maintained in glucose medium for
48 h, then OCR was measured in intact cells (5 × 106) in 1.85 ml
DMEM lacking glucose supplemented with 5% dialysed foetal
bovine serum at 37°C, as previously described (Carelli et al, 2002).
In vitro import
35S-methionine labeled peptides were generated from MTS-Cterm
and Cterm cDNAs cloned into pcDNA3.2 using a TnT Quick Coupled
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Transcription-/Translation systemTM (Promega, Fitchburg, WI,
USA). The empty vector was also used as negative control for non-
specific bands. Labelled proteins were incubated with rat liver mito-
chondria purified by differential centrifugation (Reyes et al, 2011)
for 60 min at 37°C (Petruzzella et al, 1998). Products were resolved
on 18% Tris-glycine NuPAGE SDS–PAGE gels, where one third to
one sixth of the TnT amount used in each reaction was also loaded
as control. After the run, the gels were dried and exposed to phos-
phorscreens for 5 days and scanned using a TyphoonTM phosphor-
imager (GE Healthcare, Life Sciences, Little Chalfont, UK). Additions
were 300 lg/ml trypsin, to digest proteins outside mitochondria;
FCCP (carbonylcyanide-p-trifluoromethoxyphenylhydrazone) to dis-
sipate the mitochondrial membrane potential; 0.1% Triton X-100 to
lyse the mitochondria. Mitochondrial binding was calculated as the
proportion of the labeled peptide (input TnT, first lane of each
panel) able to be pulled down or imported into either control or
uncoupled mitochondria (second and fifth lane of each panel,
respectively). Import efficiency was measured as the proportion of
the labeled mitochondrial-interacting peptide (second and fifth lane
of each panel) that was resistant to trypsin digestion in either con-
trol or uncoupled mitochondria (third or sixth lane of each panel,
respectively).
High resolution Northern
To determine the steady-state levels of mt-tRNALeu(UUR) WT, RNI64
and transiently trasformed cybrids were maintained in glucose med-
ium for 12 h and then collected for RNA extraction. Total cytosolic
RNA was obtained using Trizol reagent (Life Technologies, Paisley,
UK). RNA (1 lg) was electrophoresed through 13% denaturing
polyacrylamide gel, electroblotted onto Hybond N+ membrane (GE
Healthcare Life Sciences, Little Chalfont, UK) in 0.25 × TBE and
immobilized by ultraviolet cross-linking. Hybridization with radiola-
belled probes was performed as previously described (Taylor et al,
2003).
Surface Plasmon Resonance (SPR) experiments
Purified 5′-biotinylated human mt-tRNALeu(UUR) (bi-tRNALeu) and
5′-biotinylated mt-tRNAIle (bi-tRNAIle) were synthesized by Thermo
Scientific (Illkirch, FR).
The interaction of bi-tRNALeu or bi-tRNAIle with GST-Cterm was
studied with a BIACORE X system (Biacore AB, Uppsala, Sweden).
Two streptavidin-coated dextran sensor chips (SD, Biacore AB) were
chemically activated by a 35 ll injection of 10 mM NaOH, at a flow
rate of 10 ll/min. Bi-tRNALeu and bi-tRNAIle were immobilized via
interaction with the streptavidin surface of each chip. This proce-
dure ensures directional immobilization of the bi-tRNAs via their 5′-
termini. As a control, the sensor chips were treated as described
above in the absence of bi-tRNAs. The interaction of immobilized
bi-tRNA ligands with the GST-Cterm analyte was detected through
mass concentration-dependent changes in the refractive index on
the sensor chip surface, expressed as resonance units (RU). The
increase in RU relative to baseline indicates complex formation. The
plateau region represents the steady-state phase of the interaction,
whereas the decrease in RU indicates dissociation of the GST-Cterm
from the immobilized ligand after injection of buffer. A response
change of 1,000 RU typically corresponds to a change in the protein
concentration on the sensor chip of 1 ng/mm2.
The experiments were carried out at 298 K in degassed 20 mM
HEPES at pH 7.4, 0.15 M NaCl, and 0.005% surfactant P-20 (HBS-P
buffer). Measurements were performed at a flow rate of 30 ll/min
with an immobilization level of about 500 RU of bi-tRNALeu in the
first sensor chip, and about 550 RU of bi-tRNAIle in the second sen-
sor chip. Values of the plateau signal at steady-state (Req) were cal-
culated from kinetic evaluation of the sensorgrams using the BIA
evaluation 4.1 software (Biacore-GE Healthcare, Life Sciences, Little
Chalfont, UK). A Scatchard analysis of the dependence of Req on
the concentration of analyte was also performed to assess the equi-
librium constant of the interaction between bi-tRNAs and Cterm.
Control experiments were carried out using GST as analyte.
Bioinformatics analysis
Model building was performed with the program Phyre (http://
www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index). The three-
dimensional structure of E. coli LeuRS available from the PDB (URL:
www.rcsb.org; Berman et al, 2000) (PDB ID: 4ari, Resolution: 2.08
A) was used as template.
Structure visualization and analysis were performed using PyMol
(http://www.pymol.org/).
Statistical analysis
All data are expressed as mean  s.e.m. Data were analysed by stan-
dard ANOVA procedures followed by multiple pair-wise comparison
adjusted with Bonferroni corrections. Significance was considered at
P < 0.05. Numerical estimates were obtained with the GraphPad
InStat 3 version (GraphPad Inc., San Diego, CA, USA).
Supplementary information for this article is available online:
http://embomm.embopress.org/
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